title: Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.
authors.affiliation: Hematology and Oncology Section, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY john.mascarenhas@mssm.edu.
authors.forename: John
authors.initials: J
authors.lastname: Mascarenhas
authors.affiliation: Division of Hematology and Medical Oncology, Mayo Clinic Scottsdale, AZ.
authors.forename: Ruben
authors.initials: R
authors.lastname: Mesa
authors.affiliation: Pathology, and Genetics, Division of Hematology, University of Utah School of Medicine, UT, USA.
authors.forename: Josef
authors.initials: J
authors.lastname: Prchal
authors.affiliation: Hematology and Oncology Section, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY.
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoffman
mesh_terms: D006801:Humans; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome